From the Food and Drug Administration.
Schwetz
Bernard A
BA
D000328:Adult; D016907:Adverse Drug Reaction Reporting Systems; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000627:therapeutic use*; D018687:Antidepressive Agents, Second-Generation / Q000009:adverse effects*; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D015535:Arthritis, Psoriatic / Q000188:drug therapy*; D001549:Benzamides; D056486:Chemical and Drug Induced Liver Injury / Q000175:diagnosis* / Q000209:etiology; D003512:Cyclohexanones / Q000627:therapeutic use*; D004791:Enzyme Inhibitors / Q000627:therapeutic use*; D000068800:Etanercept; D005770:Gastrointestinal Neoplasms / Q000188:drug therapy*; D006801:Humans; D000068877:Imatinib Mesylate; D007074:Immunoglobulin G / Q000627:therapeutic use*; D007223:Infant; D017093:Liver Failure / Q000139:chemically induced*; D009579:Nitrobenzoates / Q000627:therapeutic use*; D009965:Orphan Drug Production; D010879:Piperazines / Q000627:therapeutic use*; D011743:Pyrimidines / Q000627:therapeutic use*; D018124:Receptors, Tumor Necrosis Factor / Q000627:therapeutic use*; D011993:Recombinant Fusion Proteins; D014230:Triazoles / Q000009:adverse effects*; D020176:Tyrosinemias / Q000188:drug therapy*; D014481:United States; D014486:United States Food and Drug Administration
D000894:Anti-Inflammatory Agents, Non-Steroidal; D018687:Antidepressive Agents, Second-Generation; D000970:Antineoplastic Agents; D001549:Benzamides; D003512:Cyclohexanones; D004791:Enzyme Inhibitors; D007074:Immunoglobulin G; D009579:Nitrobenzoates; D010879:Piperazines; D011743:Pyrimidines; D018124:Receptors, Tumor Necrosis Factor; D011993:Recombinant Fusion Proteins; D014230:Triazoles; C051752:nefazodone; D000068877:Imatinib Mesylate; C077073:nitisinone; D000068800:Etanercept